Dr Langer reviews how physicians can ensure that patients get access to oral selective estrogen receptor degraders (SERDs), and the panel of experts provide their closing thoughts.
Dr Langer explores how payers think about the authorization process for DEXA scans and other surveillance activities that would be required for selective estrogen receptor degraders (SERDs) and how oral SERDs affect quality of life.
Drs Vidula and Lu review the potential impact of cardiovascular health associated with oral selective estrogen receptor degraders (SERDs) and discuss how the risk of menopausal symptoms differ between oral SERDs and other endocrine therapies.
Dr Lu and Dr Vidula review the clinical impact of oral selective estrogen receptor degraders (SERDs) on disease progression and response rates in patients with ER+/HER2- metastatic breast cancer and discuss if oral SERDs can be used in combination with other therapies in patients.
Drs Langer and Vidula describe the coverage considerations for the diagnostic test required for the use of oral selective estrogen receptor degraders, best practices associated with its use, and the recommended duration of treatment.